Alpha 2.0
Login Register
» Articles » PMID: 15357519

How to Use Octreotide for Malignant Bowel Obstruction

Overview
Journal J Support Oncol
Specialty Oncology
Date 2004 Sep 11
PMID 15357519
Citations 7
Authors
Carla Ripamonti
Sebastiano Mercadante
Affiliations
Soon will be listed here.
Citing Articles

Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study.

Zucchi E, Fornasarig M, Martella L, Maiero S, Lucia E, Borsatti E Support Care Cancer. 2016; 24(7):2877-82.

PMID: 26838026 DOI: 10.1007/s00520-016-3102-9.

The use of lanreotide autogel® in the treatment of intestinal obstruction in a patient with adenocarcinoma.

Lybaert W Case Rep Oncol. 2014; 7(1):43-6.

PMID: 24575015 PMC: 3934784. DOI: 10.1159/000358124.

Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study.

Winner M, Mooney S, Hershman D, Feingold D, Allendorf J, Wright J JAMA Surg. 2013; 148(8):715-22.

PMID: 23740130 PMC: 4507521. DOI: 10.1001/jamasurg.2013.1.

Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.

Hwang M, Pirrello R, Pu M, Messer K, Roeland E Support Care Cancer. 2013; 21(10):2817-24.

PMID: 23732621 DOI: 10.1007/s00520-013-1860-1.

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review.

Tuca A Cancer Manag Res. 2010; 2:1-12.

PMID: 21188092 PMC: 3004574.